Back to top

gene-editing: Archive

Sundeep Ganoria

CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?

CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.

VRTXNegative Net Change BEAMPositive Net Change CRSPNegative Net Change

Zacks Equity Research

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

INONegative Net Change CRMDNegative Net Change KNSANegative Net Change PGENNegative Net Change